AU2014235462C1 - Deuterated palbociclib - Google Patents

Deuterated palbociclib Download PDF

Info

Publication number
AU2014235462C1
AU2014235462C1 AU2014235462A AU2014235462A AU2014235462C1 AU 2014235462 C1 AU2014235462 C1 AU 2014235462C1 AU 2014235462 A AU2014235462 A AU 2014235462A AU 2014235462 A AU2014235462 A AU 2014235462A AU 2014235462 C1 AU2014235462 C1 AU 2014235462C1
Authority
AU
Australia
Prior art keywords
compound
deuterium
same
pharmaceutically acceptable
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014235462A
Other languages
English (en)
Other versions
AU2014235462B2 (en
AU2014235462A1 (en
Inventor
Adam J. Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of AU2014235462A1 publication Critical patent/AU2014235462A1/en
Application granted granted Critical
Publication of AU2014235462B2 publication Critical patent/AU2014235462B2/en
Publication of AU2014235462C1 publication Critical patent/AU2014235462C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014235462A 2013-03-15 2014-03-12 Deuterated palbociclib Ceased AU2014235462C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787540P 2013-03-15 2013-03-15
US61/787,540 2013-03-15
PCT/US2014/024564 WO2014150925A2 (en) 2013-03-15 2014-03-12 Deuterated palbociclib

Publications (3)

Publication Number Publication Date
AU2014235462A1 AU2014235462A1 (en) 2015-09-17
AU2014235462B2 AU2014235462B2 (en) 2018-05-17
AU2014235462C1 true AU2014235462C1 (en) 2018-11-01

Family

ID=51581623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014235462A Ceased AU2014235462C1 (en) 2013-03-15 2014-03-12 Deuterated palbociclib

Country Status (8)

Country Link
US (3) US20160024084A1 (OSRAM)
EP (2) EP2970209B1 (OSRAM)
JP (1) JP2016512831A (OSRAM)
AU (1) AU2014235462C1 (OSRAM)
CA (1) CA2904054A1 (OSRAM)
EA (2) EA032094B1 (OSRAM)
MX (1) MX2015012741A (OSRAM)
WO (1) WO2014150925A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN104892604B (zh) * 2015-06-19 2016-08-24 北京康立生医药技术开发有限公司 一种cdk4抑制剂的合成方法
CN105153149B (zh) * 2015-07-29 2017-09-19 江苏中邦制药有限公司 一种选择性激酶抑制剂Palbociclib的制备方法
EP3386981B1 (en) * 2015-12-13 2021-10-13 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
CN106986871B (zh) * 2017-03-29 2019-02-26 浙江同源康医药股份有限公司 一种氘代Palbociclib的晶型及其制备方法和应用
CN106967064B (zh) * 2017-03-29 2018-03-23 郑州泰基鸿诺医药股份有限公司 氘代Palbociclib的衍生物、制备方法及其应用
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
WO2020114519A1 (zh) * 2018-12-07 2020-06-11 杭州英创医药科技有限公司 作为cdk-hdac双通路抑制剂的杂环化合物
WO2021113595A1 (en) * 2019-12-06 2021-06-10 Beta Pharma, Inc. Phosphorus derivatives as kras inhibitors
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101417A1 (en) * 2010-02-19 2011-08-25 Novartis Ag Deuterated pyrrolopyrimidine compounds as inhibitors of cdk4/6

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
JP4291696B2 (ja) * 2002-01-22 2009-07-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
JP4053073B2 (ja) * 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CN102516176A (zh) 2005-10-28 2012-06-27 雅培制药有限公司 抑制trpv1受体的吲唑衍生物
AU2007297286A1 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
JP2010513317A (ja) 2006-12-14 2010-04-30 パナシー ファーマシューティカルズ インコーポレーティッド サイクリン依存性キナーゼの阻害による神経保護方法
US20090030005A1 (en) 2007-07-19 2009-01-29 Amgen Inc. Combinations for the treatment of cancer
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
EP2242493B1 (en) * 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
CA2738925A1 (en) 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JP2012504645A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
EP3718560A3 (en) 2009-05-13 2020-12-09 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
CN101967142B (zh) * 2010-05-17 2012-05-30 苏州波锐生物医药科技有限公司 噻唑酰胺类化合物及其在治疗恶性肿瘤中的药物用途
US9808461B2 (en) 2010-11-17 2017-11-07 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011101417A1 (en) * 2010-02-19 2011-08-25 Novartis Ag Deuterated pyrrolopyrimidine compounds as inhibitors of cdk4/6

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID W. ERY ET AL., "Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.", MOLECULAR CANCER THERAPEUTICS., (2004), vol. 3, no. 11, pages 1427 - 1438 *

Also Published As

Publication number Publication date
EP2970209A2 (en) 2016-01-20
US20190225605A1 (en) 2019-07-25
WO2014150925A2 (en) 2014-09-25
EA201892726A1 (ru) 2019-04-30
EP2970209A4 (en) 2016-08-31
MX2015012741A (es) 2016-02-19
EP3492470A1 (en) 2019-06-05
US20180051022A1 (en) 2018-02-22
EP2970209B1 (en) 2018-12-26
EA201591628A1 (ru) 2016-03-31
WO2014150925A3 (en) 2014-12-04
AU2014235462B2 (en) 2018-05-17
AU2014235462A1 (en) 2015-09-17
CA2904054A1 (en) 2014-09-25
US20160024084A1 (en) 2016-01-28
EA032094B1 (ru) 2019-04-30
JP2016512831A (ja) 2016-05-09

Similar Documents

Publication Publication Date Title
AU2014235462C1 (en) Deuterated palbociclib
AU2013296627B2 (en) Deuterated ibrutinib
WO2012151361A1 (en) Carbamoylpyridone derivatives
AU2014205472B2 (en) Deuterated momelotinib
WO2014011971A2 (en) Deuterated carfilzomib
US20130109707A1 (en) Fluorouracil derivatives
WO2018005328A1 (en) Deuterated bictegravir
WO2012154728A1 (en) Deuterated n-butyl bumetanide
US9676790B2 (en) Substituted thienotriazolodiazapines
WO2012129381A1 (en) Deuterated preladenant
CA2904148A1 (en) Deuterated pacritinib
WO2015009889A1 (en) Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2012027579A1 (en) Synthetic triterpenoid derivatives
EP2804857A1 (en) Deuterated alpha-lipoic acid
WO2014008417A1 (en) Deuterated vercirnon

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 JUL 2018

TH Corrigenda

Free format text: IN VOL 32 , NO 30 , PAGE(S) 4293 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME CONCERT PHARMACEUTICALS, INC., APPLICATION NO. 2014235462 CORRECT THE DATE OF THE STATEMENTS FILED TO READ 20 AND 24 JUL 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENTS FILED 20 JUL 2018 AND 24 JULY 2018

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired